The association between health-related quality of life and achievement of personalized symptom goal

Tagami, Keita; Kawaguchi, Takashi; Miura, Tomofumi; Yamaguchi, Takuhiro; Matsumoto, Yoshihisa; Watanabe, Yuki; Uehara, Yuko; Okizaki, Ayumi; Inoue, Akira; Morita, Tatsuya; Kinoshita, Hiroya

doi:10.1007/s00520-020-05316-0

Cited by 11 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previous RCT was performed for outpatients 5 ; however, this study was for inpatients. However, mean changes of fatigue NRS showed similar levels to the previous RCT 5 and previous observation studies 7 , 13 ; therefore, we were able to create this study design using the RCT's criteria. This study failed to validate the RCT's results; however, dexamethasone 8 mg p.o.…”

Section: Discussionmentioning

confidence: 54%

“…PSG-fatigue was assessed by asking the patients, “at what level would you feel comfortable with fatigue?” to identify the maximal symptom intensity they would consider comfortable on a 0 to 10 NRS. 12 , 13 The achievement of PSG-fatigue was defined as fatigue intensity from ESASr-J lower than the PSG-fatigue score. 12 , 13 …”

Section: Methodsmentioning

confidence: 99%

“… 12 , 13 The achievement of PSG-fatigue was defined as fatigue intensity from ESASr-J lower than the PSG-fatigue score. 12 , 13 …”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Dexamethasone 8 mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial

Miura

Okizaki

Hasuo

et al. 2021

Palliative Medicine Reports

Self Cite

View full text Add to dashboard Cite

Objective: No standard treatment for cancer-related fatigue (CRF) for inpatients in a palliative care setting exists. The aim of this study was to validate the previous study-derived efficacy of dexamethasone 8 mg for CRF among inpatients in a palliative care setting. Methods: Inpatients with moderate fatigue (≥4/10) were enrolled in a multicenter phase II trial. Dexamethasone 8 mg p.o. or 6.6 mg i.v. was administered for seven days and 4 mg p.o. or 3.3 mg i.v. for seven consecutive days. The primary endpoint was a threshold average change of Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue subscale score of 3. The secondary endpoints were evaluated with the anorexia-cachexia subscale (ACS), and the Edmonton symptom assessment scale-revised Japanese version. Results: A total of 32 patients were enrolled. On day 8, the mean change of FACIT-fatigue subscale from day 1 was 5.2 (95% confidence interval 0.8–10.0), in which the lower bound was above 0 but not above the prespecified threshold value of 3.0 ( p = 0.72). Edmonton symptom assessment system (ESAS)-fatigue was significantly improved by day 3 ( p = 0.02), but not on day 8 or day 15. ACS, physical well-being, and ESAS-lack of appetite significantly improved by day 8 and day 15. Adverse events were tolerable. Conclusion: This study showed that dexamethasone 8 mg failed to achieve the preset efficacy for CRF among inpatients in a palliative care setting. However, this treatment improved fatigue and would be an option for CRF. jRCT (jRCTs031180068).

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Dexamethasone 8 mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial

Miura

Okizaki

Hasuo

et al. 2021

Palliative Medicine Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…We are using the PRO version of the Common Terminology Criteria for Adverse Events (CTCAE)23 and the CTCAE v.5.0 to assess adverse events. We are evaluating pain severity using the Brief Pain Inventory (BPI)-Short Form (SF)24 and Personalized Pain Goal (PPG) 25…”

Section: Methods and Analysismentioning

confidence: 99%

Psychological barriers to the use of opioid analgesics for treating pain in patients with advanced recurrent cancer (BAROC): protocol for a multicentre cohort study

et al. 2022

Self Cite

View full text Add to dashboard Cite

IntroductionOpioid analgesics are essential for treating cancer pain. However, patients are sometimes reluctant to use them because of concerns about addiction and dependence. Rapid pain relief following opioid administration may help overcome the psychological barriers to opioid analgesic use. This study aims to determine the relationship between psychological resistance to strong opioid analgesic use and pain amelioration speed in patients with advanced recurrent cancer.Methods and analysisThis ongoing, multicentre, observational study enrols patients aged 20 years or older with distant metastasis or advanced recurrent cancer receiving strong opioid analgesics for cancer pain for the first time. All participants, both inpatient and outpatient, were recruited from five Japanese hospitals. We are investigating the relationship between psychological barriers at the start of treatment and pain relief during the first week of treatment in these patients. The primary outcome is the Japanese version of the Barriers Questionnaire-II score at baseline. The secondary outcomes are the relationships between psychological barriers to strong opioid analgesic use and changes in pain over time. The participants are asked to fill out an electronic patient-reported outcome daily during the first week of treatment. The sample size was determined based on the number of patients in the year prior to study commencement who used strong opioid analgesics, met the eligibility criteria and could be expected to consent to participate in the study.Ethics and disseminationThe study protocol was approved by the ethics committee (approval ID B200600091) of Yokohama City University on 24 August 2020. The protocol has been reviewed by the institutional review boards at the four participating study sites. The results will be published in a peer-reviewed journal and will be presented at a relevant meeting.Trial registration numberUMIN000042443.

show abstract

“…The cervical cancer women who were undertaking CCRT would suffer more complications and side effects than those receiving surgery alone (6)(7)(8)(9). The multiple co-occurring symptoms has been proved to be one of the most important factors that would influence the QoL among cancer survivors negatively (10). However, most studies on cervical cancer placed their focus on the impact of certain single symptom rather than symptom clusters on QoL (11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Symptom Clusters and Quality of Life in Cervical Cancer Patients Receiving Concurrent Chemoradiotherapy: The Mediating Role of Illness Perceptions

et al. 2022

View full text Add to dashboard Cite

ObjectivesAlthough studies shows that symptom clusters and illness perceptions are negatively associated with quality of life (QoL), it is unclear how these variables of cervical cancer patients who receive concurrent chemoradiotherapy (CCRT) relate to each other. This study aimed to identify the symptom clusters in cervical cancer patients who receive CCRT and evaluate the mediating effect of illness perceptions on the relationship between symptom clusters and QoL.MethodsA cross-sectional survey was conducted on 286 cervical cancer patients receiving CCRT from October 2019 to October 2020. M.D. Anderson Symptom Inventory, Brief Illness Perception Questionnaire, and Functional Assessment Cancer Therapy-Cervix were applied to investigate the symptom clusters, illness perceptions and QoL of the participants, respectively. Exploratory factor analysis was conducted to identify symptom clusters. The relationships among symptom clusters, illness perceptions, and QoL were analyzed with the structural equation modeling.ResultsA total of four symptom clusters were identified, including psychological status symptom cluster, therapy side-effect symptom cluster, sickness symptom cluster, and gastrointestinal symptom cluster (χ2 = 1,552.282, Df = 78, P < 0.001). Symptom clusters, illness perceptions, and QoL were significantly correlated. Symptom clusters had significant direct (β = −0.38, P < 0.001) and indirect effects (β = −0.21, P < 0.001) on QoL.ConclusionIllness perceptions played a significant mediating role between symptom clusters and QoL in cervical cancer patients receiving CCRT. Strategies like prompting effective symptom management for the purposes of alleviating illness perceptions may contribute to improving their QoL.

show abstract

The association between health-related quality of life and achievement of personalized symptom goal

Cited by 11 publications

References 22 publications

Dexamethasone 8 mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial

Dexamethasone 8 mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial

Psychological barriers to the use of opioid analgesics for treating pain in patients with advanced recurrent cancer (BAROC): protocol for a multicentre cohort study

Symptom Clusters and Quality of Life in Cervical Cancer Patients Receiving Concurrent Chemoradiotherapy: The Mediating Role of Illness Perceptions

Contact Info

Product

Resources

About